Tarlatamab-Dlle. Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 1 mg, 10 mg
Reference Brands: Imdelltra (USA), Imdylltra (EU/UK)
Category: Oncology Cancer Care
Tarlatamab-dlle is a bispecific T-cell engager (BiTE) antibody that binds DLL3 on small cell lung cancer cells and CD3 on T cells, enabling targeted immune killing of tumor cells. It is approved for adults with extensive-stage small cell lung cancer who have progressed after platinum-based chemotherapy. It has shown meaningful response rates and durable clinical benefit in resistant disease. The treatment is given by step-up intravenous infusion to reduce the risk of cytokine release syndrome. Patients are monitored closely for immune-related reactions and neurological side effects. Tarlatamab-dlle. is available in Injection and strengths such as 1 mg, 10 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Tarlatamab-dlle. is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Tarlatamab-dlle. can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Tarlatamab-dlle is used for the treatment of extensive-stage small cell lung cancer (ES-SCLC) in adults who have disease progression after platinum-based chemotherapy.
It is made from a bispecific T-cell engager (BiTE) antibody construct that binds to DLL3 on tumor cells and CD3 on T-cells to trigger targeted immune-mediated killing.
The trade name is Imdelltra.
It is manufactured and marketed by Amgen Inc.
The generic name is tarlatamab-dlle.
The brand name is Imdelltra.
It is manufactured by Amgen at its biologics production facilities in the United States.
Related Products
Momelotinib
Strength:
100 mg, 150 mg, 200 mg
Form: Tablets
Reference Brands: Ojjaara (USA)
View Details
Nirogacestat
Strength:
50 mg
Form: Tablets
Reference Brands: Generic formulations marketed under different names
View Details
Nintedanib
Strength:
100 mg, 150 mg
Form: Capsules
Reference Brands: Ofev (USA, EU), Vargatef (EU)
View DetailsQuick Response Guaranteed | Verified Suppliers
